The transcription of protein-encoding genes in eukaryotic cells requires RNA polymerase II and a set of general transcription factors that include the TATA-binding protein (TBP), TFIIB, TFIIE, TFIIF and TFIIH (reviewed in [1]). These factors assemble at the core promoter and are sufficient for accurate transcription initiation in vitro. Transcriptional activators -which bind sequence-specific enhancer elements located upstream of the core promoter -stimulate the rate of transcription in response to physiological or developmental stimuli. A third class of transcription factors, known as coactivators or 'mediators', facilitate the interaction between the sequence-specific activators and the general RNA polymerase II machinery.
The first coactivators to be identified were the TBPassociated factors (TAFs) -the non-TBP subunits of general transcription factor TFIID. Whereas TBP is sufficient for basal transcription in vitro, TFIID is required for activated transcription in metazoan systems. Interestingly, however, TAFs are not required for activation in yeast cell-free systems, despite the presence of TFIID in yeast. Instead, a mediator complex, referred to here as SRB/MED, was identified on the basis of its requirement for activation in vitro (reviewed in [2] ). SRB/MED comprises a subset of SRB proteins, identified genetically as suppressors of truncations of the carboxyterminal repeat domain of the largest subunit of RNA polymerase II, a novel set of proteins denoted MEDs, and several polypeptides identified as either positive or negative effectors of transcription (reviewed in [3] ).
Another form of the SRB/MED complex was independently identified as a component of a yeast RNA polymerase II holoenzyme complex. The two SRB/MED complexes are nearly identical, although a notable difference is the absence of Srb8-Srb11 in the functionally-defined mediator complex. Interestingly, these SRB proteins were initially identified in genetic screens as negative effectors of transcription. The structural differences between the two complexes can then be explained by the different purification strategies. Whereas mediator was isolated based on its requirement for activation, the holoenzyme was initially purified independently of any functional requirement. This is an important difference, because it implies the existence of functionally distinct SRB/MED subcomplexes (reviewed in [3] ). Indeed, recent results [4] have confirmed the modular nature of the yeast SRB/MED complex and demonstrated that specific functions can be attributed to each subcomplex ( Figure 1 ).
Human homologs of SRB and MED proteins have been identified, raising the possibility that SRB/MED complexes also function in higher organisms. Affinity purification of human Srb10 -also known as Cdk8 -yielded a multisubunit complex, designated NAT, that includes homologs of several SRB/MED components but is devoid of RNA polymerase II [5] . However, NAT functions as a general repressor of activated transcription, rather than as a coactivator. NAT catalyzes phosphorylation of the RNA polymerase II carboxy-terminal repeat domain, but in contrast to TFIIH, it does so prior to assembly of the preinitiation complex. The same temporal specificity has been defined for the yeast Srb10-Srb11 heterodimer [6] , which is likely to account for the repressive effects of both complexes on transcription.
Other complexes that include SRB and MED proteins have been identified independently in human and mouse cells [7, 8] . The SMCC complex was affinity purified from human cells expressing epitope-tagged SRB proteins and is structurally similar to NAT. In contrast to NAT, however, SMCC also mediates transcriptional activation, albeit in a manner dependent upon another coactivator, PC4 [7, 9] . A mouse complex, mMED, that includes homologs of yeast SRB/MED proteins has also been identified. mMED was purified by conventional chromatography and contains a protein similar to a mitogen-activated protein (MAP) kinase, suggesting that SRB/MED complexes might be terminal components of signal transduction pathways [8] .
The identification of the NAT, SMCC and mMED complexes established the existence of SRB/MED-like complexes in mammalian cells. But what is the range of activators (or repressors) whose activities are mediated by these complexes? Recent studies have linked specific activator proteins to their cognate coactivator complexes.
The TRAP and DRIP complexes were identified as cofactors that mediate ligand-dependent activation by the thyroid hormone receptor and the vitamin D3 receptor, respectively [10, 11] . Another SRB/MED complex, denoted human mediator (hMED), was identified as a cofactor for multiple activators, including E1A, VP16 and Elk1 [12] . Further characterization of SMCC showed that it acts as a cofactor of activation by thyroid hormone receptor, VP16 and p53 [9] . All of these complexes share common subunits and they are probably identical. Thus, a broad range of activators stimulate transcription through the same, or related, SRB/MED complexes.
A mammalian SRB/MED complex distinct from those described above was identified as a mediator of Sp1 activation [13] . This complex, denoted CRSP, appears to be a subcomplex of the larger SRB/MED complex, suggesting that different SRB/MED complexes can be assembled from a subset of SRB/MED components to meet the needs of specific activators. This scenario is comparable to the two SRB/MED complexes identified in yeast, only one of which includes the Srb8-Srb11 subcomplex. The modular nature of SRB/MED complexes is also suggested by genome-wide analysis of yeast srb and med mutations, some of which cause global transcriptional defects, whereas others affect expression of only a subset of genes [14] .
These studies investigated the cofactor requirements for individual activators. Many genes, however, are regulated by multiple enhancer elements that bind distinct activators. Furthermore, multiple activators often act synergistically to stimulate transcription. How does this complexity affect coactivator requirements? This issue was recently addressed in the case of cooperative activation by Sp1 and the sterol-regulated factor SREBP-1a at the promoter of the gene for the low-density lipoprotein receptor [15] . A multisubunit coactivator complex that acts in a chromatindependent manner on this promoter was identified. This cofactor, designated ARC, is not specific for SREBP-1a and Sp1, but also mediates activation by VP16 and NF-κB [16] . Moreover, ARC turns out to be identical to TRAP/DRIP/SMCC [9, 11, 16] . Thus, a single coactivator can mediate synergistic activation, presumably by providing binding sites for multiple activators (Figure 1 ).
How do the TAFs fit into this picture of coactivation mediated by SRB/MED complexes? As noted above, the yeast SRB/MED complex mediates activation in a TAFindependent manner. Yet in mammalian systems, TAFs appeared to be required coactivators that act in concert with other coactivators. This principle was recently challenged by the observation that the thyroid hormone receptor can stimulate transcription on naked DNA templates in a TRAP-dependent, TAF-independent manner [10] . This result not only shows that TAFs can be dispensable for activation in mammalian systems, but indicates the functional redundancy that exists among coactivator complexes. Genetic analysis of coactivator requirements in yeast led to a similar conclusion [17] .
The findings on mammalian SRB/MED coactivator complexes underscore the conserved nature of the RNA polymerase II transcriptional machinery among eukaryotes. Nevertheless, the mechanism by which these factors affect transcription remains poorly defined. The yeast SRB/MED complex is tightly associated with RNA polymerase II and acts, at least in part, through the latter's carboxy-terminal repeat domain. The mammalian SRB/MED complexes also interact with RNA polymerase II, but this interaction occurs independently of the carboxy-terminal repeat domain for both NAT and SMCC [5, 7] . The ARC and DRIP complexes are reported to function in a chromatindependent manner, whereas CRSP, SMCC and hMED Dispatch R607
Figure 1
Transcriptional activation. Activator proteins -A1, A2, A3 -bind to cognate enhancer elements and interact directly with coactivators and/or components of the core transcriptional machinery, including RNA polymerase II and the general transcription factors (GTFs). Coactivators shown here include SWI/SNF (chromatin remodeling complex), SAGA (histone acetyltransferase complex), SRB/MED (mediator) and the TAF subunits of TFIID. The modular nature of the SRB/MED complex is highlighted by labeling the Srb4, Srb10, Med7 and Rgr1 subcomplexes, each of which includes several polypeptides [3, 4] . SRB/MED interacts directly with RNA polymerase II through the latter's carboxy-terminal repeat domain to form a holoenzyme complex in yeast [3] ; mammalian SRB/MED complexes also interact with RNA polymerase II, but independently of the carboxy-terminal repeat domain [5, 7] . Many activators stimulate transcription by recruiting TBP to the core promoter, a process that occurs synergistically with other core factors, including RNA polymerase II, TFIIB and the Srb4 component of SRB/MED [21, 22] . mediate activation on naked DNA templates. This distinction might, however, reflect differences in the assay conditions, rather than real functional differences among the complexes. Regardless, these issues highlight our nascent understanding of SRB/MED functions.
In addition to TAFs and SRB/MEDs, transcriptional coactivators include chromatin remodeling factors and histone acetyltransferases (Figure 1 ). These coactivators work in a manner mechanistically distinct from SRB/MEDs. The SWI/SNF chromatin remodeling complex and the SAGA histone acetyltransferase complex are both required for activation of the HO gene in yeast. The assembly of these factors at the HO promoter was recently investigated by DNA crosslinking and immunoprecipitation analyses [18, 19] . The promoter-specific transcription factor Swi5 initiates activation by recruiting SWI/SNF, which in turn recruits SAGA. The activities of these two coactivators are essential for recruitment of another sequence-specific factor, Swi4-Swi6, which presumably facilitates assembly of the preinitiation complex. These results define the temporal relationship among factors affecting HO expression. An earlier report [20] that the SWI/SNF complex is a component of the yeast RNA polymerase II holoenzyme also raises the interesting possibility that Swi5 recruits the holoenzyme, which in turn recruits SAGA.
DNA crosslinking and immunoprecipitation experiments have also been used to study assembly of the transcription preinitiation complex. Two related studies [21, 22] investigated the requirements for TBP occupancy of promoter DNA in yeast. A general correlation was found between TBP binding and transcriptional activity, consistent with the premise that activators stimulate TBP recruitment to promoter DNA. TBP recruitment was, however, dependent upon additional factors, including RNA polymerase II, TFIIB and Srb4. These results directly demonstrate that activators can stimulate assembly of the transcription preinitiation complex. Moreover, the observation of activator-mediated, cooperative assembly of the preinitiation complex challenges the notion that TBP recruitment is the principal, rate-limiting step in transcription.
The ability of diverse activators to act through common SRB/MED coactivators simplifies our understanding of activation. Nonetheless, SRB/MED complexes are intricate structures composed of multiple subunits with illdefined functions. Many fundamental questions remain unanswered. Do the different SRB/MED complexes exist as pre-assembled structures, or are they assembled de novo in response to specific activators and repressors? What accounts for the functional distinctions among SRB/MED complexes in their response to unique activators and repressors? Most importantly, how do SRB/MED complexes communicate with the core transcriptional machinery to regulate transcription? The answers to these questions will come from the powerful combination of genetic and biochemical approaches, using both yeast and mammalian systems.
